Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

被引：0
|
作者：
J. F. W. Hoogkamer
C. H. Kleinbloesem
M. Ouwerkerk
A. Högemann
A. Nokhodian
W. Kirch
E. Weidekamm
机构：
[1] Clin-Pharma Research,
[2] CH-4127 Birsfelden,undefined
[3] Switzerland Tel.: +41-61-313 3220; Fax: +41-61-313 3242,undefined
[4] Takeda Euro Research and Development Centre,undefined
[5] Frankfurt am Main,undefined
[6] Germany,undefined
[7] Medizinische Fakultät Technische Universität Dresden,undefined
[8] Dresden,undefined
[9] Germany,undefined
来源：
European Journal of Clinical Pharmacology | 1998年 / 54卷
关键词：
Key words Candesartan; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: The influence of liver disease on the pharmacokinetics of candesartan, a long-acting selective AT1 subtype angiotensin II receptor antagonist was studied.
引用
收藏
页码：341 / 345
页数：4
相关论文
共 50 条
  • [31] Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
    deZeeuw, D
    Remuzzi, G
    Kirch, W
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 : S37 - S42
  • [32] PHARMACOKINETICS OF CEFOTETAN IN NORMAL SUBJECTS AND PATIENTS WITH IMPAIRED RENAL-FUNCTION
    OHKAWA, M
    HIRANO, S
    TOKUNAGA, S
    MOTOI, I
    SHODA, R
    IKEDA, A
    SUGATA, T
    SAWAKI, M
    SHIMAMURA, M
    OKASHO, A
    KURODA, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (01) : 31 - 35
  • [33] PHARMACOKINETICS OF FLUCYTOSINE IN NORMAL SUBJECTS AND PATIENTS WITH IMPAIRED RENAL-FUNCTION
    KELLY, MR
    BLAIR, AD
    FORREY, AW
    CUTLER, RE
    CLINICAL RESEARCH, 1976, 24 (02): : A92 - A92
  • [34] Steady state pharmacokinetics of nefazodone in subjects with normal and impaired renal function
    Barbhaiya, RH
    Brady, ME
    Shukla, UA
    Greene, DS
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 49 (03) : 229 - 235
  • [35] PHARMACOKINETICS OF AMANTADINE HYDROCHLORIDE IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
    HORADAM, VW
    SHARP, JG
    SMILACK, JD
    MCANALLEY, BH
    GARRIOTT, JC
    STEPHENS, MK
    PRATI, RC
    BRATER, DC
    ANNALS OF INTERNAL MEDICINE, 1981, 94 (04) : 454 - 458
  • [36] PHARMACOKINETICS OF CEFMETAZOLE IN NORMAL SUBJECTS AND IN PATIENTS WITH IMPAIRED RENAL-FUNCTION
    OHKAWA, M
    ORITO, M
    SUGATA, T
    SHIMAMURA, M
    SAWAKI, M
    NAKASHITA, E
    KURODA, K
    SASAHARA, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (03) : 386 - 389
  • [37] PHARMACOKINETICS OF DAPRODUSTAT AND METABOLITES IN SUBJECTS WITH NORMAL AND IMPAIRED HEPATIC FUNCTION.
    Shaddinger, B.
    Andrews, S.
    Mahar, K.
    Ramanjineyulu, B.
    Caltabiano, S.
    Lindsay, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S92 - S92
  • [38] PHARMACOKINETICS OF ENALAPRIL AND LISINOPRIL IN SUBJECTS WITH NORMAL AND IMPAIRED HEPATIC-FUNCTION
    HAYES, PC
    PLEVRIS, JN
    BOUCHIER, IAD
    JOURNAL OF HUMAN HYPERTENSION, 1989, 3 : 153 - 158
  • [39] Pharmacokinetics of single dose cerivastatin in subjects with normal and impaired renal function
    Vormfelde, SV
    Gleiter, CH
    Freudenthaler, S
    Muck, W
    Schmage, N
    Kuhlmann, J
    GundertRemy, U
    ATHEROSCLEROSIS, 1997, 130 : 127 - 127
  • [40] PHARMACOKINETICS OF CEFOTIAM IV IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
    HOFFLER, D
    KOEPPE, P
    ACTA THERAPEUTICA, 1989, 15 (01) : 3 - 16
12345